New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of ...

The schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...

Former smokers with COPD reporting higher perceived stress had poorer scores on respiratory health assessments, according to ...

CHRONOS 研究首次为 COPD 前驱期或早期阶段的干预提供了临床证据，证实了三联疗法在改善小气道功能和症状方面的有效性，为 COPD 的早期治疗开辟了新路径。同时，哮喘治疗向精准化、个体化方向的转变，也为哮喘患者的管理提供了更科学的策略。这些研究成果不仅丰富了呼吸系统疾病的治疗理论，更有望通过早期干预和精准治疗显著改善患者的生活质量，降低疾病负担，对推动呼吸医学领域的发展具有重要意义。

While exacerbations are more frequent and severe as COPD progresses, patients with COPD may exacerbate for a variety of reasons. For example, pollution, cigarette smoke and upper respiratory tract ...

There was evidence that patients on the drug improved their health compared to those on standard care, as measured by the COPD Assessment Test (CAT) but, overall, the full data is less than ...

The five-repetition sit-to-stand test (5STS) is a test of lower limb function that measures the fastest time taken to stand five times from a chair with arms folded. The 5STS has been validated in ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

Paul T. Kelly, MSc; Maureen P. Swanney, PhD; Leigh M. Seccombe, MSc; Chris Frampton, PhD; Matthew J. Peters, MD, PhD, FCCP; Lutz Beckert, MD, FCCP This research was ...